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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine the effectiveness of single or multicomponent non-pharmacological interventions in reducing the symptoms, duration
or severity of an established episode of delirium in hospitalised people outside intensive care settings.
B A C K G R O U N D
Delirium is a common cause and complication of hospitalisation
in older people (Ryan 2013; Siddiqi 2006). Estimates of delir-
ium occurrence vary depending on the setting. In a recent Italian
point prevalence study in older hospital inpatients, 21.2% of pa-
tients on general medical wards, 24.7% on geriatric wards, 20.6%
on orthopaedic wards and 14% of those in rehabilitation beds
were delirious (Bellelli 2016). Occurrence rates of greater than
50% have been reported in those at particularly high risk (co-inci-
dent dementia, older age, severe illness or perioperatively) (Inouye
2014; Ryan 2013). Prevention of delirium is possible through non-
pharmacological means. Ameta-analysis of randomised controlled
trials (RCTs) showed that multicomponent interventions reduce
incident delirium by about 30% (Siddiqi 2016). However, once
established, delirium confers a poor prognosis, with evidence to
suggest development, or progression, of lasting cognitive impair-
ment (Gross 2012; MacLullich 2009; McCusker 2001); increased
mortality (Witlox 2010), especially in the context of frailty (Eeles
2012); and increased risk of institutionalisation (O’Keefe 1997;
Pendlebury 2015). Delirium is a deeply unpleasant experience for
patients andmay result in lasting psychological sequelae (Morandi
2015; O’Malley 2008). There are no established treatments for
delirium; UK best practice guidelines advise judicious use of an-
tipsychotic medications at low doses aimed at reducing the symp-
toms of agitation and psychiatric symptoms of hyperactive delir-
ium (NICE 2010). However, there is little trial evidence to suggest
this approach either reduces the severity or duration of delirium,
or improves outcomes. It is also not known whether interventions
aimed at modifying the risk factors for delirium can attenuate or
shorten a delirium episode.
Description of the condition
Delirium is a syndrome with diverse and multiple aetiologies. Al-
though several risk factors have been identified, its pathophysiol-
ogy remains uncertain. A number of brain neural networks and
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pathways have been implicated (MacLullich 2013), but mech-
anisms remain poorly understood. Delirium is characterised by
rapid onset of fluctuating impairments in consciousness (arousal
or attention) and cognition (memory, language, orientation, visu-
ospatial ability, perception). Hallucinations and disturbance of the
sleep/wake cycle are common. People with delirium often exhibit
behavioural disturbances in keeping with hypo- and hyperactive
delirium subtypes (39% and 21% of delirium episodes respec-
tively). Fluctuation in symptoms is an important feature of delir-
ium, and commonly people will switch betweenmotor behaviours
resulting in a third subtype: ’mixed’ delirium (27% of delirium
episodes). Approximately 14% of patients exhibit no motor symp-
toms (Bellelli 2016). The degree to which individual delirium fea-
tures are present for an individual is variable and determines delir-
ium severity. There may be profound disturbances of attention,
awareness and cognition, or these may be present in a mild form
that can be difficult to detect. Fluctuation of delirium severity
within an individual is a key feature of delirium.
Diagnosis of delirium remains clinical and depends onmeeting di-
agnostic criteria outlined in the Diagnostic and Statistical Manual
for Mental Disorders (DSM-V; APA 2013). Delirium can only be
diagnosed if the neurocognitive disturbance is due to a physiolog-
ical consequence of a medical condition, substance withdrawal,
toxicity or secondary to multiple aetiologies. Previous iterations
of these diagnostic criteria have been operationalised into delir-
ium assessment tools, such as the Confusion Assessment Method
(CAM) (Inouye 2000), and the Delirium Rating Scale - Revised
1998 (DRS-R-98) (Trzepacz 1988; Trzepacz 2001). Delirium as-
sessment tools may underestimate symptoms of hypoactive delir-
ium. Detection of delirium with these instruments is operator-
dependent and relies on adequate training.
Delirium duration is very variable and episodes may last from a
few days to several months. Persistence of delirium beyond hos-
pital discharge is common; meta-analysis of available prevalence
estimates and different time points revealed 44.7% of patients still
had evidence of delirium at hospital discharge, and about half of
these had recovered by three months post discharge (Cole 2009).
Up to 1 in 5 patients still had features of delirium at six months
post hospital discharge and the relationship with more longer-
lasting cognitive decline is poorly understood. People with pre-
existing dementia are more likely to develop persistent delirium
and their outcomes are particularly poor (Cole 2009).
A number of factors predispose to delirium and some of these
cannot be modified. In some circumstances therefore, e.g. at the
end of life or advanced frailty, deliriummay be all but inevitable in
the presence of a physiological stressor. Identification of effective
treatment strategies that lessen symptoms or shorten the duration
of delirium remain important.
Description of the intervention
Treatment of delirium may be pharmacological or non-pharma-
cological. A Cochrane Review found some evidence to support
the use of antipsychotic medication for the treatment of delir-
ium (Lonergan 2007). Attention to the factors contributing to an
episode of delirium may also be an effective treatment strategy.
This Cochrane Review therefore aims to determine whether non-
pharmacological interventions aimed at modification of delirium
risk factors can attenuate established delirium.
Non-pharmacological interventions for the treatment of delirium
may be targeted at ward level, e.g. modification of the ward envi-
ronment or educational interventions to enable nurses and clini-
cians better to identify and manage delirium (Cole 2002; Milisen
2001; Naughton 2005; NICE 2010). Interventions could also be
personalised to identify and attenuate risk factors specific to an
individual, e.g. strategies to manage pain or improve hydration.
Multicomponent interventions may attempt to target several risk
factors simultaneously through the use of standardised protocols,
staff and carer education, or systems redesign (e.g. proactive geri-
atric consultation) (Cole 2002;Milisen 2001; Pitkälä 2006); these
may have components targeted at both award and individual level.
An effective delirium treatment intervention may be aimed at re-
lieving the distress that delirium causes, reducing associated harm-
ful complications (such as falls) or attenuating delirium severity
rather than resolution of the delirium episode.
How the intervention might work
Reducing known precipitants of and risk factors for delirium will
decrease the burden of factors contributing to (and possibly per-
petuating) an episode of established delirium (NICE 2010). This
may reduce the severity and duration of the episode. There is evi-
dence that multicomponent interventions targeted at several risk
factors concurrently are effective in prevention of delirium (reduc-
tion in incident delirium of about one-third) (Siddiqi 2016).
Why it is important to do this review
Pharmacological treatment strategies for delirium are currently
aimed at reducing symptoms of hyperactivity. Removing or mod-
ifying factors likely to be contributing to an episode of delirium
is a common clinical treatment strategy but this approach is un-
supported by the current evidence base: it is unclear whether an
episode of established delirium can be attenuated through non-
pharmacological strategies.
This Cochrane Review aims to establish the clinical effectiveness
of non-pharmacological interventions for the treatment of estab-
lished delirium, through examination of randomised and cluster-
randomised trials. This will help to inform service design for the
management of this distressing and harmful condition in older
people.
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O B J E C T I V E S
To determine the effectiveness of single or multicomponent non-
pharmacological interventions in reducing the symptoms, dura-
tion or severity of an established episode of delirium in hospitalised
people outside intensive care settings.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include all randomised controlled trials (RCTs), including
cluster-RCTs.
Types of participants
We will include studies of patients with a diagnosis of delirium
made either through fulfilment of the Diagnostic and Statistical
Manual forMental Disorders (DSM-V) (APA 2013), or the Inter-
national Classification ofDiseases (ICD10) criteria (WHO 2016),
as assessed by a clinician or with a validated delirium assessment
tool. We will include studies of delirium where the diagnosis is
made at presentation (prevalent delirium) or during the course of
hospital admission (incident delirium), but only where the inter-
vention is aimed at treating established delirium.
We will include studies performed in patients aged 16 years or
over, admitted to medical or surgical wards in general hospitals.
We will exclude studies in intensive care unit settings, and studies
of delirium associated with substance intoxication or withdrawal
as the physiological stressors and population are different in these
circumstances. We will consider studies of delirium in palliative
care settings separately as delirium is a common complication of
end of life care, where the focus of treatment is often control of
symptoms (Hosker 2016).
Types of interventions
We will include trials that compare non-pharmacological inter-
ventions designed to treat delirium with usual care. Also we will
include trials that compare an active control intervention. Trials
of interventions aimed at single risk factors (e.g. medication re-
view, hydration, re-orientation, occupational or physiotherapy in-
terventions) or multicomponent interventions (combining one or
more of these risk factors) will be eligible for inclusion. Interven-
tions may be implemented at a ward or individual level. We will
include studies of multicomponent interventions where one of the
components is a pharmacological agent provided the drug is not
the focus of the intervention. We will consider these types of in-
terventions separately to interventions without a pharmacological
component.
Types of outcome measures
We will include studies if they report any of the primary or sec-
ondary outcomes relating to the study of a multicomponent inter-
vention. We will include studies that measure duration or severity
of delirium through patient experience or patient-reported out-
comes (e.g. relating to a reduction in delirium symptoms or im-
proved quality of life).
Primary outcomes
• Duration of delirium, measured as either the number of
days that delirium is detected using a validated delirium
diagnostic method or the duration of the episode as reported by
study authors. We will only include studies in which clinical
experts (psychiatrists, old age psychiatrists, geriatricians) or
clinical or research staff trained according to standardised
training methods performed the delirium assessments.
Secondary outcomes
• Peak reported delirium severity measured by a validated
instrument such as the Delirium Rating Scale Revised 1998
(DRS-R98) (Trzepacz 2001), Memorial Delirium Assessment
Scale (MDAS) (Breibart 1997), or Delirium Rating Scale
(Trzepacz 1988), by assessors trained using standardised
methods.
• Length of hospital admission.
• New diagnosis of dementia made between 1 and 3 months,
6 and 12 months, and beyond 12 months from randomisation.
• Progression of existing dementia measured with a validated
scale between 1 and 3 months, 6 and 12 months, and beyond 12
months from randomisation.
• Use of psychotropic medicines during admission.
• Delirium symptoms including cognitive, perceptual,
psychotic, affective and behavioural disturbance during
admission measured through objective or patient experience
measures (e.g. Delirium Observation Screening Scale
(Schuurmans 2003)).
• New move to institutional care facilities at discharge,
between 1 and 3 months, 6 and 12 months, and beyond 12
months from randomisation.
• Activities of daily living between 1 and 3 months, 6 and 12
months, and beyond 12 months from randomisation.
• Quality of life (through validated patient reported measure)
between 1 and 3 months, 6 and 12 months, and beyond 12
months from randomisation.
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• Carer’s quality of life (reported through validated carer-
reported measure) between 1 and 3 months, 6 and 12 months,
and beyond 12 months from randomisation.
• Direct costs of interventions.
• Cost-effectiveness of interventions.
• Withdrawal from protocol by participants.
Adverse events
• Readmission to acute hospital within 30 days of discharge.
• Falls.
• Pressure ulcers.
• Nosocomial infections.
• Mortality as an inpatient, between 1 and 3 months, 6 and
12 months, and beyond 12 months from randomisation
We will use GRADEpro Guideline Development Tool (GDT)
software to determine the overall quality of the evidence and to
generate a ’Summary of findings’ table for the key primary and sec-
ondary outcomes of duration of delirium, peak reported delirium
severity, length of hospital admission, new move to institutional
care facilities at discharge, new diagnosis of dementia or progres-
sion of existing dementia, and the adverse event of mortality as an
inpatient (GRADEpro 2014).
Search methods for identification of studies
Electronic searches
We will search the specialised register of the Cochrane
Dementia and Cognitive Impairment Group (ALOIS) (
www.medicine.ox.ac.uk/alois).Wewill search for all RCTs or non-
pharmacological interventions for treating delirium.
ALOIS contains records from all major healthcare databases. The
Information Specialist of the Cochrane Dementia and Cogni-
tive Impairment Group maintains ALOIS, which contains stud-
ies about dementia and cognitive impairment identified from the
following.
• Monthly searches of a number of major healthcare
databases: MEDLINE, Embase, CINAHL, PsychINFO and
LILACs.
• Monthly searches of a number of trials registers: the
metaRegister of Controlled Trials, the Umin Japan Trial Register,
the World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) portal (which covers
ClinicalTrials.gov, ISRCTN Registry, the Chinese Clinical Trials
Register, the German Clinical Trials Register, the Iranian
Registry of Clinical Trials and The Netherlands Clinical Trials
Register, plus others).
• Quarterly searches of the Cochrane Library’s Central
Register of Controlled Trials (CENTRAL).
• Monthly searches of a number of a grey literature sources:
ISI Web of Knowledge Conference Proceedings, Index to
Theses, and Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website (www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia, cognitive
improvement and cognitive enhancement trials, can be viewed in
the ‘methods used in reviews’ section within the editorial informa-
tion about the Cochrane Dementia and Cognitive Improvement
Group.
We will run additional searches in MEDLINE, Embase,
PsycINFO, CINAHL, ClinicalTrials.gov and the World Health
Organization (WHO) International Clinical Trials Registry Plat-
form (ICTRP) portal to ensure that the searches for each suite of
reviews are as comprehensive and as up-to-date as possible. We
have presented the search strategy that we will use for the retrieval
of reports of trials from MEDLINE (via the Ovid SP platform)
in Appendix 1. There will be no time or language restraints on
literature searches.
Searching other resources
We will examine reference lists of retrieved articles and relevant
reviews to identify any additional potential trials for inclusion.
We will perform a search of the ClinicalTrials.gov database, to
identify any relevant ongoing trials.We will compare the trials that
meet the inclusion criteria of our review with the trials register to
identify any trials where results are unpublished. We will contact
the lead author of any unpublished trials and request results. We
will examine published reports against their protocols to ensure
per protocol analysis has occurred. The search for ongoing clinical
trials will help to inform future updates of this Cochrane Review.
Data collection and analysis
Selection of studies
We will merge the results of the literature search into Covidence
software (Covidence 2017).We will collate multiple reports of the
same studies and we will remove duplicates. Two review authors
with experience in conducting systematic reviews will indepen-
dently screen the titles and abstracts of the articles identified from
the literature searches and will exclude irrelevant titles. We will
resolve any disagreement by consensus with a third review author.
Two review authors will independently examine the full-text arti-
cles of potentially relevant studies against the stated eligibility cri-
teria, and will resolve any disagreements by consensus with a third
review author. If there is insufficient information in the full-text
article, we will contact the study authors for clarification. We will
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list all articles excluded after full-text assessment and their reasons
for exclusion in a ’Characteristics of excluded studies’ table. We
will present the study selection process in a PRISMA diagram.
Data extraction and management
Two review authors will extract data using a piloted data extrac-
tion tool. We will resolve any disagreements regarding data ex-
traction by consensus with a third review author. We will pro-
duce ’Characteristics of included studies’ tables, ’Characteristics
of excluded studies’ tables, ’Characteristics of ongoing trials’ ta-
bles and a ’Summary of findings’ tables using Review Manager
5 (RevMan 5) (Review Manager 2014), and GRADEpro GDT
software (GRADEpro 2014). We will extract data from multiple
reports of the same study directly into a single data extraction
form.
Assessment of risk of bias in included studies
Two review authors will independently determine the risk of bias
as either high, low or unclear against the criteria identified in the
Cochrane Handbook of Systematic Reviews of Interventions (Higgins
2011). We will resolve any disagreements through reaching a con-
sensus with a third review author. We will assess included trials for
adequacy of sequence generation, allocation concealment, blind-
ing (of participants, personnel and of outcome assessors), incom-
plete outcome data, selective outcome reporting and other sources
of bias. Cluster-RCTs are subject to additional biases: recruitment
bias (recruitment of individual study participants after randomisa-
tion of clusters), chance between-cluster baseline imbalances due
to a small number of clusters, loss of clusters (e.g. withdrawal of a
study site), not accounting for clustering during the analysis (in-
correct unit of analysis issues) or bias introduced through combin-
ing data from cluster- and individually-randomised trials in meta-
analyses (risk of underestimation of treatment effects). We will
generate summaries of risk of bias in RevMan 5 (Review Manager
2014). We will include additional rows in the ’Risk of bias’ tables
specifically to assess for the potential biases associated with cluster-
RCTs.
Measures of treatment effect
We anticipate that we will find a combination of continuous and
dichotomous outcome measures across included studies. Where
possible we will undertake meta-analysis of extracted data using
RevMan 5 (Review Manager 2014). We will calculate between
group (intervention vs control) mean differences in the continu-
ous outcomeswith 95%confidence intervals (CIs). Theminimally
important difference (MID) for the primary outcome of delirium
duration will be one day. Where studies report the same outcome
measured with different instruments, we will report standardised
mean difference (SMD) values with 95% CIs. Where SMD are
used, the MID will be based on detection of a small effect size
(SMD of less than 0.4). For any dichotomous secondary outcome
measure, we will calculate risk ratios (RRs) (intervention vs con-
trol) with 95% CIs. We will analyse time-to-event data with haz-
ard ratios (HRs). If an included study does not report data to de-
termine the primary outcomes, we will attempt to obtain data by
contacting the study authors directly.
Unit of analysis issues
We expect some included studies to use a cluster-randomised de-
sign.Where these studies have analysed data using statistical meth-
ods that account for clustering, we will extract the adjusted effect
measures (RR or HR) and their 95% CIs. If an included study
has performed unadjusted analyses we will approximate corrected
analyses by extracting data on the number of clusters, mean size of
each cluster, primary outcome data and estimates of intra-cluster
correlation coefficient (ICC). If approximately corrected analyses
are not possible, then we will extract the primary data and calcu-
late RRs with 95% CIs.
Dealing with missing data
We will assess missing outcome data due to attrition or exclusions
for each included study. If available, we will report the reasons for
incomplete outcomes data due to participants or clusters lost to
follow-up. Where a study has not reported relevant data, we will
try to obtain these data by contacting the study authors directly.
We will perform available-case analysis and will only include cases
where outcomes are known. We will report incomplete outcomes
data in ’Risk of bias’ tables and will include an assessment of the
potential impact of missing data on the results.
Assessment of heterogeneity
The nature of complex interventions for delirium treatment is
likely to result in both clinical and methodological heterogeneity.
We will complete an assessment of clinical heterogeneity among
the treatments identified. Where synthesis is appropriate, we will
estimate the extent of (combined) heterogeneity across studies in-
cluded in the meta-analysis by using the I² statistic.
Assessment of reporting biases
We will compare the studies included in our review against
databases and international registries of clinical trials to identify
trials with unpublished results. We will examine published studies
against their protocols to ensure protocol adherence. A search for
ongoing clinical trials will identify studies that should be included
in future updates of this Cochrane Review.
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Data synthesis
Wewill performmeta-analyses using a random-effects inverse vari-
ance model. We will present pooled RRs with 95% CIs for di-
chotomous outcomes and pooled mean differences with 95% CIs
for continuous outcomes (standardised if the included studies have
used different instruments to measure the same outcome).We will
synthesise outcomes from appropriately adjusted cluster-RCTs us-
ing generic inverse variance models.We will not synthesise data for
meta-analysis if clinical heterogeneity is such that we cannot make
valid outcome comparisons; instead we will undertake a narrative
evidence synthesis.
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analyses for individuals in trials with
and without a clinical diagnosis of dementia or frailty (measured
with a validated instrument).
Sensitivity analysis
We will perform sensitivity analyses where appropriate following
our assessment of the risk of methodological bias in the included
trials. This will include sensitivity analysis of studies where a phar-
macological agents forms part of a multicomponent intervention.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. Delirium/
2. deliri*.mp.
3. “acute confusion*”.ti,ab.
4. “acute organic psychosyndrome”.ti,ab.
5. “acute brain syndrome”.ti,ab.
6. “metabolic encephalopathy”.ti,ab.
7. “acute psycho-organic syndrome”.ti,ab.
8. “clouded state”.ti,ab.
9. “clouding of consciousness”.ti,ab.
10. “exogenous psychosis”.ti,ab.
11. “toxic psychosis”.ti,ab.
12. “toxic confusion”.ti,ab.
13. Delirium, Dementia, Amnestic, Cognitive Disorders/su [Surgery]
14. obnubilat*.ti,ab.
15. or/1-14
16. (coordinat* OR “co-ordinat*”).ti,ab.
17. prevent*.mp.
18. reduc*.ti,ab.
19. stop*.ti,ab.
20. taper*.ti,ab.
21. avoid*.ti,ab.
22. “cut* down”.ti,ab.
23. manag*.ti,ab.
24. prog*.ti,ab.
25. or/16-24
26. 15 and 25
27. randomized controlled trial.pt.
28. controlled clinical trial.pt.
29. randomi?ed.ab.
30. placebo.ab.
31. drug therapy.fs.
32. randomly.ab.
33. trial.ab.
34. groups.ab.
35. or/27-34
36. (animals not (humans and animals)).sh.
37. 35 not 36
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